Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ondansetron - Transcept Pharmaceuticals

Next Previous
Search
Drug Profile

Ondansetron - Transcept Pharmaceuticals

Alternative Names: Setrodon; TO-2061

Latest Information Update: 31 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transcept Pharmaceuticals
  • Developer Transcept Pharmaceuticals Inc
  • Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Pyrimidinones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Obsessive-compulsive disorders

Most Recent Events

  • 17 Jan 2013 Transcept Pharmaceuticals terminates its phase II trial in Obsessive compulsive disorders in USA and Mexico (NCT01275248)
  • 21 Dec 2012 Discontinued - Phase-II for Obsessive-compulsive disorders in Mexico (PO)
  • 21 Dec 2012 Discontinued - Phase-II for Obsessive-compulsive disorders in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top